Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 6/2012

01-11-2012 | Case Report

Adult hypophosphatasia with painful periarticular calcification treated with surgical resection

Authors: Kei-ichiro Iida, Jun-ichi Fukushi, Toshifumi Fujiwara, Yoshinao Oda, Yukihide Iwamoto

Published in: Journal of Bone and Mineral Metabolism | Issue 6/2012

Login to get access

Abstract

Hypophosphatasia is a rare inherited disorder characterized by a low serum alkaline phosphatase (ALP) activity and defective bone mineralization. Adult hypophosphatasia typically manifests in middle-age as a result of osteomalacia with recurrent stress fractures of the lower limb. However, considerable variation occurs in the clinical expression of hypophosphatasia, and no curative treatment has yet been established. We herein report a case of adult hypophosphatasia with painful calcific periarthritis, which showed improvement after surgical resection. A 32-year-old male was referred to our clinic complaining of pain in his elbows and knees. A painful subcutaneous mass was palpable on his right lateral epicondyle, where periarticular calcification was detected by plain radiography. The laboratory data showed a slight decrease in serum ALP activity and bone mineral density, and an elevation in the urinary phosphoethanolamine. Genomic DNA sequencing revealed an F310L mutation and a Y246H polymorphism in the tissue-nonspecific alkaline phosphatase gene, confirming the diagnosis of hypophosphatasia. The pain in the patient’s right elbow was not responsive to nonsteroidal anti-inflammatory drugs, and triamcinolone diacetate was locally injected for treatment. His symptoms were ameliorated after the injection; however, they recurred in 3 months, and he became refractory to additional steroid injection. Surgical debridement of the calcified lesion was performed, and his symptoms were successfully ameliorated after the surgery.
Literature
1.
go back to reference Whyte MP, Mumm S, Deal C (2007) Adult hypophosphatasia treated with teriparatide. J Clin Endocrinol Metab 92:1203–1208PubMedCrossRef Whyte MP, Mumm S, Deal C (2007) Adult hypophosphatasia treated with teriparatide. J Clin Endocrinol Metab 92:1203–1208PubMedCrossRef
2.
go back to reference Wendling D, Jeannin-Louys L, Kremer P, Fellmann F, Toussirot E, Mornet E (2001) Adult hypophosphatasia. Current aspects. Joint Bone Spine 68:120–124PubMedCrossRef Wendling D, Jeannin-Louys L, Kremer P, Fellmann F, Toussirot E, Mornet E (2001) Adult hypophosphatasia. Current aspects. Joint Bone Spine 68:120–124PubMedCrossRef
3.
go back to reference Beck C, Morbach H, Richl P, Stenzel M, Girschick HJ (2009) How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? Rheumatol Int 29:229–238PubMedCrossRef Beck C, Morbach H, Richl P, Stenzel M, Girschick HJ (2009) How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? Rheumatol Int 29:229–238PubMedCrossRef
4.
go back to reference Macfarlane JD, Kroon HM, Cats A (1986) Ectopic calcification in hypophosphatasia. Eur J Radiol 6:228–230PubMed Macfarlane JD, Kroon HM, Cats A (1986) Ectopic calcification in hypophosphatasia. Eur J Radiol 6:228–230PubMed
5.
go back to reference Caspi D, Rosenbach TO, Yaron M, McCarty DJ, Graff E (1988) Periarthritis associated with basic calcium phosphate crystal deposition and low levels of serum alkaline phosphatase—report of three cases from one family. J Rheumatol 15:823–827PubMed Caspi D, Rosenbach TO, Yaron M, McCarty DJ, Graff E (1988) Periarthritis associated with basic calcium phosphate crystal deposition and low levels of serum alkaline phosphatase—report of three cases from one family. J Rheumatol 15:823–827PubMed
6.
go back to reference Chuck AJ, Pattrick MG, Hamilton E, Wilson R, Doherty M (1989) Crystal deposition in hypophosphatasia: a reappraisal. Ann Rheum Dis 48:571–576PubMedCrossRef Chuck AJ, Pattrick MG, Hamilton E, Wilson R, Doherty M (1989) Crystal deposition in hypophosphatasia: a reappraisal. Ann Rheum Dis 48:571–576PubMedCrossRef
8.
go back to reference Mornet E (2000) Hypophosphatasia: the mutations in the tissue-nonspecific alkaline phosphatase gene. Hum Mutat 15:309–315PubMedCrossRef Mornet E (2000) Hypophosphatasia: the mutations in the tissue-nonspecific alkaline phosphatase gene. Hum Mutat 15:309–315PubMedCrossRef
9.
go back to reference Millán JL, Narisawa S, Lemire I, Loisel TP, Boileau G, Leonard P, Gramatikova S, Terkeltaub R, Camacho NP, McKee MD, Crine P, Whyte MP (2008) Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res 23:777–787PubMedCrossRef Millán JL, Narisawa S, Lemire I, Loisel TP, Boileau G, Leonard P, Gramatikova S, Terkeltaub R, Camacho NP, McKee MD, Crine P, Whyte MP (2008) Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res 23:777–787PubMedCrossRef
10.
go back to reference Eade AW, Swannell AJ, Williamson N (1981) Pyrophosphate arthropathy in hypophosphatasia. Ann Rheum Dis 40:164–170PubMedCrossRef Eade AW, Swannell AJ, Williamson N (1981) Pyrophosphate arthropathy in hypophosphatasia. Ann Rheum Dis 40:164–170PubMedCrossRef
11.
go back to reference Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241PubMedCrossRef Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241PubMedCrossRef
12.
go back to reference Zurutuza L, Muller F, Gibrat JF, Taillandier A, Simon-Bouy B, Serre JL, Mornet E (1999) Correlations of genotype and phenotype in hypophosphatasia. Hum Mol Genet 8:1039–1046PubMedCrossRef Zurutuza L, Muller F, Gibrat JF, Taillandier A, Simon-Bouy B, Serre JL, Mornet E (1999) Correlations of genotype and phenotype in hypophosphatasia. Hum Mol Genet 8:1039–1046PubMedCrossRef
13.
go back to reference Fauvert D, Brun-Heath I, Lia-Baldini AS, Bellazi L, Taillandier A, Serre JL, de Mazancourt P, Mornet E (2009) Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles. BMC Med Genet 10:51PubMedCrossRef Fauvert D, Brun-Heath I, Lia-Baldini AS, Bellazi L, Taillandier A, Serre JL, de Mazancourt P, Mornet E (2009) Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles. BMC Med Genet 10:51PubMedCrossRef
14.
go back to reference Michigami T, Uchihashi T, Suzuki A, Tachikawa K, Nakajima S, Ozono K (2005) Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia. Eur J Pediatr 164:277–282PubMedCrossRef Michigami T, Uchihashi T, Suzuki A, Tachikawa K, Nakajima S, Ozono K (2005) Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia. Eur J Pediatr 164:277–282PubMedCrossRef
15.
go back to reference Ozono K, Yamagata M, Michigami T, Nakajima S, Sakai N, Cai G, Satomura K, Yasui N, Okada S, Nakayama M (1996) Identification of novel missense mutations (Phe310Leu and Gly439Arg) in a neonatal case of hypophosphatasia. J Clin Endocrinol Metab 81:4458–4461PubMedCrossRef Ozono K, Yamagata M, Michigami T, Nakajima S, Sakai N, Cai G, Satomura K, Yasui N, Okada S, Nakayama M (1996) Identification of novel missense mutations (Phe310Leu and Gly439Arg) in a neonatal case of hypophosphatasia. J Clin Endocrinol Metab 81:4458–4461PubMedCrossRef
16.
go back to reference Mornet E, Taillandier A, Peyramaure S, Kaper F, Muller F, Brenner R, Bussiere P, Freisinger P, Godard J, Le Merrer M, Oury JF, Plauchu H, Puddu R, Rival JM, Superti-Furga A, Touraine RL, Serre JL, Simon-Bouy B (1998) Identification of fifteen novel mutations in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in European patients with severe hypophosphatasia. Eur J Hum Genet 6:308–314PubMedCrossRef Mornet E, Taillandier A, Peyramaure S, Kaper F, Muller F, Brenner R, Bussiere P, Freisinger P, Godard J, Le Merrer M, Oury JF, Plauchu H, Puddu R, Rival JM, Superti-Furga A, Touraine RL, Serre JL, Simon-Bouy B (1998) Identification of fifteen novel mutations in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in European patients with severe hypophosphatasia. Eur J Hum Genet 6:308–314PubMedCrossRef
17.
go back to reference Henthorn PS, Ferrero A, Fedde KN, Coburn SP, Whyte MP (1996) Hypophosphatasia mutation D361V exhibits dominant effects both in vitro and in vivo. Am J Hum Genet 59:A119 Henthorn PS, Ferrero A, Fedde KN, Coburn SP, Whyte MP (1996) Hypophosphatasia mutation D361V exhibits dominant effects both in vitro and in vivo. Am J Hum Genet 59:A119
Metadata
Title
Adult hypophosphatasia with painful periarticular calcification treated with surgical resection
Authors
Kei-ichiro Iida
Jun-ichi Fukushi
Toshifumi Fujiwara
Yoshinao Oda
Yukihide Iwamoto
Publication date
01-11-2012
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 6/2012
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-011-0338-9

Other articles of this Issue 6/2012

Journal of Bone and Mineral Metabolism 6/2012 Go to the issue

List of Reviewers 2011-2012

LIST OF REVIEWERS 2011–2012

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine